Compare PMT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | TBPH |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 879.9M | 908.9M |
| IPO Year | 2009 | 2013 |
| Metric | PMT | TBPH |
|---|---|---|
| Price | $9.50 | $16.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $13.50 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 1.3M | 486.4K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $351,067,000.00 | $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | $24.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.05 | $13.08 |
| 52 Week High | $13.80 | $21.03 |
| Indicator | PMT | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 55.26 |
| Support Level | $9.05 | $16.80 |
| Resistance Level | $9.83 | $17.17 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 62.42 | 70.00 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.